Novel Radionuclides - Don’t Forget the Regulatory Side

Recent years have seen many efforts to investigate several novel radionuclides, currently neither commercially available nor clinically used. Especially with the advent of theranostics aims are to improve therapeutic efficacy, to adapt the physical half live to the target under investigation or to improve the “matched pair” concept, i.e. eliminating differences in chemistry between a diagnostic and therapeutic radionuclides. This pre-Congress symposium will discuss, which candidates are promising, how technical and organisational advances may lead to better availability, where are major challenges, what is clinically required and desired, where are regulatory hurdles and where we currently stand in the development. The views from the producers, preclinical radiopharmaceutical researchers and the clinician will be included to provide an up to date status.